PATENT CLAIM ANALYSIS

Application Number: 16194696
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-06
Patent Classification: ["514", "210210"]

Abstract:
Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions. Trk inhibitors are useful in the treatment of inflammatory diseases, autoimmune disease, defects of bone metabolism and/or cancer, and are particularly useful in the treatment of osteoarthritis (OA), pain, and pain associated with OA. Trk inhibitors are also useful for inhibiting tropomyosin-related kinase A (TrkA), tropomyosin-related kinase B (TrkB), tropomyosin-related kinase C (TrkC), and/or c-FMS (the cellular receptor for colony stimulating factor-1 (CSF-1)).

Claim (Index 48):
A pharmaceutical composition comprising a compound according to  claim 1 .

Metadata:
- Claim Count in Document: 37.0
- Percentile: 98.0
- Lexical Diversity: 2.03509
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15436195', '14741017', '11115003', '15101798', '13121900']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7739890583801128
- 35 USC 102 Novelty (BERT): 0.5851912569323164
- Combined Prediction Score: 0.7551092782353332
- Mean Citation Score: 415.879788
- Max Citation Score: 528.4177
- Similarity Product: 387.25573836846354

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test